A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer

5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates

CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses

New investigational targeted therapeutic, entrectinib, shows early promise

Paediatric and adult high grade gliomas: A tale of a histone tail

Galectins in tumour immunity

Treatment of relapsed myeloma with novel targeted and immune therapies

Targeting T regs in tumours

Multiplex IHC as biomarkers for cancer immunotherapy

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity

Understanding personalised medicine - the e-learning course

Mechanisms of immune escape in non-Hodgkin lymphoma